No headlines found.
No press releases found.
No news found.
The Fund is an actively managed exchange-traded fund that, seeks daily investment results, before fees and expenses, that correlate to two times (2x) the daily performance of the SPDR S&P Biotech ETF ("Underlying ETF"). For purposes of the Fund's name, "U.S. Biotech" refers to U.S. biotechnology equity exposure, primarily biotechnology and life sciences companies, as represented by the Underlying ETF. The Fund seeks to achieve its objective on a single trading day basis only; returns for periods longer than one trading day will be the result of each day's returns compounded over the period and should not be expected to equal two times (2x) the cumulative performance of the Underlying ETF for the same period. To pursue its 2x Daily Objective, the Fund expects to obtain most of its exposure through derivatives, primarily through total return swap agreements with major financial institutions, whereby the Fund and the swap counterparty agree to exchange the return on a notional amount linked to the Underlying ETF or a basket of its constituents, calculated on a daily basis, to provide leveraged exposure equal to approximately 200% of the Fund's net assets.
Corgi U.S. Biotech 2X Daily ETF trades on the BATS stock market under the symbol XBIX.
As of July 17, 2026, XBIX stock price climbed to $35.73 with 623 million shares trading.
XBIX has a market cap of $714,536.00. This is considered a Sub-Micro Cap stock.
XBIX support price is $33.12 and resistance is $36.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBIX shares will trade within this expected range on the day.
